Virology & Infectious Diseases RFP Opportunities
Supports research advancing HIV prevention/treatment, hepatitis B/C/D care, and AmBisome antifungal therapy to improve clinical outcomes and patient care.
Funder: Gilead Sciences
Due Dates: January 30, 2026 (LOI, HIV Prevention - INCLUSION Global 2026) | May 4, 2026 (LOI, HIV: RESONATE 2026, BIC/LEN) | June 30, 2026 (LOI, AmBisome topic area)
Funding Amounts: Up to $5,000,000 (INCLUSION Global) or $4,000,000 (RESONATE) total program funds; typical project duration up to 18–24 months; overhead capped at 30%.
Summary: Supports high-impact research on HIV prevention/treatment, AmBisome antifungal therapy, and hepatitis B/C/D care models, with an emphasis on clinical innovation and improved patient outcomes.
Key Information: LOIs must be submitted via Gilead OPTICS; eligibility and scope vary by RFP and topic.
Description
Gilead Sciences’ Virology & Infectious Diseases RFP Opportunities provide funding for investigator-initiated and collaborative research focused on advancing care and outcomes in HIV, hepatitis B/C/D, and antifungal (AmBisome) therapy. The program supports studies addressing implementation research, clinical and community decision-making, safety and efficacy of therapies, epidemiology, and strategies to improve linkage to care. Specific RFPs under this umbrella include HIV Prevention (INCLUSION Global 2026), HIV Treatment (RESONATE 2026, BIC/LEN), and AmBisome antifungal research, with each program featuring its own priorities and eligibility criteria.
